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Abstract
Objective: Although clinical trial participants are the most affected by research ethics committee’s
decisions, they are not formally represented on Swiss committees. We aimed to find out what
patients think about the idea of being members of such committees.
Design: Latent thematic analysis was used to analyse the interviews.
Setting: Patients were recruited in a Swiss university hospital.
Participants: The study involved 26 patients suffering from diabetes or gout.
Interventions: We conducted semi-structured interviews.
Main Outcome Measures: We explored what patients think of being established members of
research ethics committees.
Results: We identified three different attitudes among our participants regarding participation in
research ethics committees: (i) positive attitude regarding the idea of being members of such com-
mittees, (ii) ambivalent attitude and (iii) negative attitude. Patients belonging to the first group (i)
often mentioned that they wanted their health condition to be more visible. Patients from the
second group (ii) mentioned positive as well as negative aspects. Patients from the third group (iii)
said that patients in general did not have enough background knowledge to be able to gain an
overview of a whole clinical trial.
Conclusions: Our study adds important knowledge about the idea of patients becoming research
ethics committee members by exploring their perceptions of being members. Stable patients
tended to be interested in the idea of participation and some specific recommendations could be
derived (patients could have an advisory instead of a decision-making role on committees).
However, further studies with more patients and further quantitative research are needed.
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Introduction
According to the Declaration of Helsinki, every trial involving
human beings must be approved by a research ethics committee
(REC) in advance. Each committee member must be independent of
the researcher and sponsor and must operate free of any other
inappropriate influence [1]. RECs are constituted by members of dif-
ferent specialities (e.g. physicians, statisticians and ethicists). In the
UK, RECs need to include so-called ‘lay members’ who are inde-
pendent of health services. Half of them are required to never have
worked in the healthcare sector. Some RECs also include patient
representatives [2]. Swiss RECs are similar as they include experts
from different scientific disciplines, but they are not required to
include lay members [2, 3]. Nevertheless, each state (canton) of the
federalist Swiss Confederation can decide whether its REC needs to
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include lay persons, defined as any person who is not a physician.
However, the lay person is not necessarily a representative of
patients [4]. While three cantonal RECs (Zurich, St. Gallen, Vaud)
employ patient representatives, only 1.6% of Swiss REC members
are patient representatives [4]. In contrast, 41.5% are physicians [4].
This means that although clinical trial (CT) participants are the
group most affected by the REC’s decisions, they are not formally
represented on Swiss RECs [3]. Including patient representatives on
RECs, however, is not necessarily enough to support patient inter-
ests. The question is whether patient representatives are able to
speak for patients who suffer from other diseases. Therefore, it
might be helpful to include patients rather than patient representa-
tives or lay members in RECs and decision-making regarding CTs to
ensure that patients’ voices are heard [2].
A possible disadvantage of having patients as REC members
could be the whole process of recruiting appropriate patients (e.g.
stable patients), which could be very costly and time consuming
[2]. CTs involving novel technologies (e.g. synthetic biology) and
stable patients (i.e. not terminally ill), are more likely to be rejected
because RECs consider it highly risky to enrol stable patients in
first-in-human (FIH) trials. In these cases, the potential damage to
health outweighs the potential benefit for volunteering participants
[2]. Terminally ill cancer patients are a common target group for
CTs, given the absence of alternative treatment options. However,
decisions of patients who have a life-threatening illness may be
strongly affected by the lack of treatment alternatives [5]. Indeed,
patients with a high degree of psychological strain might be more
likely to accept possibly high risks and be victims of the therapeutic
misconception (i.e. lacking awareness of the difference between
clinical research and therapeutic treatment) [6]. Moreover, the
informed consent process itself can be exhausting for severely ill
patients and be considered as too harmful [7]. Enroling stable
patients in FIH trials (e.g. diabetes patients) could be a way to
avoid these ethical issues. Stable patients have more treatment
options than near-death cancer patients. Hence, they are more
likely to make free choices [5] and less likely to fall victim to the
therapeutic misconception [6]. Additionally, they might benefit
from the medications developed through CTs since despite limited
quality of life, life expectancy is only slightly decreased [8, 9].
Therefore, RECs’ tendency to reject high-risk studies involving
stable patients could be criticized as unjustified paternalism [10,
11]. It has been argued that stable patients are capable of giving
reflective ‘independent’ answers [5] and should be allowed to
decide whether to take trial related risks. McKinstry [12] concludes
that paternalism, especially with respect to competent patients, is
rarely justified. Respect for patient autonomy is one of the four
principles of modern biomedical ethics [13]. Two prerequisites for
a person to be autonomous are identified: liberty and agency. This
means that a person can decide independently, free from others’
influence and has the capacity to act in an intentional manner [13].
Autonomy has acquired increased importance in medicine [7].
Failing to consider patients’ willingness to accept risks, i.e. the
paternalistic attitude of RECs [2, 11], seems to create an anachron-
istic situation regarding autonomy. This situation could lead to the
patient’s right to make autonomous decisions regarding participa-
tion in clinical research being restricted. Therefore, shifting from
paternalistic decision-making to a patient-centred and shared
decision-making by putting patients on RECs increases patients’
ability to engage in autonomous decision-making [14]. Thus,
patients should have the opportunity to participate in decision-
making regarding CTs.
Aim of the study
Given the identified advantages and disadvantages of a system
where RECs include patients as members [2], we aimed to find out
what stable patients think about being members of RECs.
Therefore, we explored this issue using qualitative interviews from a
broader study on FIH trials with stable patients.
Methods
We employed an empirical research design with the overall goal of
exploring stable patients’ attitudes towards participation in RECs as
established members. The data were gathered as a part of a larger inter-
view study where patients were asked about their attitudes towards syn-
thetic biology and related CTs [15]. A pilot study was carried out in
order to ensure patients’ understanding. We used the 32-item checklist
from consolidated criteria for reporting qualitative research (COREQ)
[16]. We obtained ethical approval from the local REC.
Sampling and data collection
The interview study involved a purposive sample of patients suffer-
ing from diabetes or gout. Inclusion criteria for this study were that
patients were (i) >18 years, (ii) stable and (iii) suffered either from
diabetes or gout. The recruitment was carried out in the hospital
during a time period of six months in 2014/2015 while patients
were there for a routine check-up. Our recruiting physicians
approached suitable patients and asked if they would be interested
in participating in an interview study. Subsequently, a research
assistant (trained in qualitative research) went to the hospital and
asked patients if they agreed to participate. In case of agreement,
patients received a participant information sheet, and an informed
consent form and were given time to consider whether to consent.
Afterwards, the research assistant approached the patients via phone
or email and made an appointment. The interview took place at
the patient’s home, our research institute, or in the hospital. During
the interview only the interviewer and the interviewee were present
in the room. All interviews were conducted by the same research
assistant. Written informed consent was obtained from all partici-
pants. On average, the interviews lasted for 44min (range:
16–102min). All interviews were conducted in Swiss German, tran-
scribed verbatim and fully anonymized.
Interview guide
After a literature search for research on cutting edge biotechnology, we
developed an interview guide. Based on the previous literature research,
we selected topics which should be included in our interview guide
(e.g. examples of CTs and patients’ current health status). The semi-
structured interview guide provided a short explanation of our study
and of RECs, followed by two questions regarding patients’ opinion
on RECs (Table 1). These two questions were specifically analysed in
this paper.
Analysis
Of the 36 patients, 26 answered the question about the topic of patient
representation in RECs. Overall, 10 patients responded that due to not
knowing the concept of RECs they could not give an appropriate
answer. Here, we present and analyse the responses of the remaining
26 patients. We used latent thematic analysis as it is independent of a
particular theory or epistemology. Therefore, it can be applied across
different approaches [17]. The project did not intent to develop a
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theory or understand the experiences of the patients, but to study their
opinions on participation on RECs. First, all authors read the
interview-transcripts in order to inductively obtain preliminary themes
that are not a priori defined based on a theory [17]. The authors dis-
cussed the preliminary themes. Afterwards, we agreed on themes and
coded the transcripts according to the agreed themes. Member check
was done by the co-authors. During the analysis for the questions ana-
lysed for this article, data saturation was reached according to Guest
et al. [18]. The final themes are presented in Results.
Study population
In total 88% (n = 23) of the patients were males; age ranged from 26
to 91 years. Other demographic information is presented in Table 2.
Results
We identified three different attitudes regarding participation on
RECs: (i) exclusively mentioning positive aspects, (ii) ambivalence
about the idea and (iii) exclusively mentioning negative aspects.
Positive aspects of being members of RECs
The majority were very positive about patient participation in RECs.
Participants often mentioned their own benefit as a reason to participate
as members. More precisely, patients saw a chance of a long-term bene-
fit on their own health condition from participating in RECs and per-
haps allowing more CTs. Another frequent reason was that patients
wanted their situation to be visible. Patients also said that they have
experience with the disease and therefore they can tell what it is like to
live with it. For this reason, they should be able to integrate their opi-
nions on whether a CT should be performed within an REC. Another
reason for patient participation in RECS was that they possibly add dif-
ferent perspectives on a certain aspect of the disease (Table 3).
Ambivalent aspects of being members of RECs
A smaller second group of patients was ambivalent. Participants
mentioned both positive (e.g. to see what is happening; patients
experience) and negative aspects (e.g. patients may not have enough
knowledge; they only see their own benefit) of being on RECs. Some
patients said that it does not necessarily have to be patients but inde-
pendent people who are on the committee (Table 4).
Negative aspects of being members of RECs
Finally, a few patients did not see any positive aspects of making
patients members of RECs. The main reason cited regarding why
patients should not be part of RECs was that they do not have
enough expertise to be able to gain an overview of the whole study.
In addition, participants mentioned that they did not understand the
purpose of having ordinary people on a REC (Table 5).
In summary, our analysis showed that most participants were
positive about the idea of being members of RECs. Interviewees illu-
strated their experience and their comprehension of the disease, but
also their interest in propelling research. Many patients think that
present RECs do not pay enough attention to their health condition,
and that only patients are able to assess it.
Table 2 Descriptive statistics of our study population (n = 26)
Gender (male) 88.5%





• ≤ Two person 88.5%
• > Three person 7.7%
Disease
• Diabetes mellitus I 23.1%
• Diabetes mellitus II 38.5%
• Gout 38.5%
*M = mean; SD = standard deviation.
Table 1 Questions about research ethics committees
Before a new type of treatment (e.g. gout or diabetes capsules) can be
tested on patients within clinical trials, a committee of experts decides
whether this trial may to take place at all. This committee assesses the
possible risks and benefits related to this trial, and weigh them up
against each other. In Switzerland there are many different ideas
about who should be represented in such a committee.
1. What do you think about this? Who should be represented in such a
committee and why?
2. How do you see the participation of patients in such committees?
Table 3 Positive aspects of being members of RECs
Patient 8: This would be good. [Good] in the sense that they [patients]
talk from experience, they know what happens in the body [e.g.] of a
diabetes patient. In my opinion there should be both types of diabetes
patients in there [committees]. This would mirror the reality very well
(…), because they [diabetes patients] know what they are talking
about and you can rely on their opinion. This would be the main goal
that these kinds of people [patients] are represented in such
committees (…), people who know the problem (diabetes diagnosis
10 years ago).
Patient 1: To be able to see the patients’ situation. He/she can, only he/
she can, say how hard the disability is, caused by the disease. He/she
can estimate the agony caused by the disease. A physician is not able
nor is a psychologist, right. That is something only the patient can
(…) and I think that [patients] should be heard and incorporated [in
RECS] (gout diagnosis one year ago).
Patient 7: Because they [patients] are interested that science gets on (…),
because there are a lot of things that do not work 100% yet. This
could be a reason that they [patients] are interested in being part of
such committees and maybe they can positively influence the whole
thing (gout diagnosis <1 year ago).
Patient 16: Because he/she [patient] can maybe add some things, which might
get forgotten by more educated people (diabetes diagnosis 3 years ago).
Table 4 Ambivalent aspects of being members of RECs
Patient 25: There are pros and cons (…) which speak for and against it,
right. Patients have some experiences as well. (…) if there are more
[patients], there is an exchange of ideas and they could talk together
and accordingly influence something in a positive or negative way
(diabetes diagnosis 15 years ago).
Patient 36: I think that is delicate, because the ‘ego-thinking’ comes up
again, yes that could bring something or it [drug, treatment] could
help a little bit. I do not think so (gout diagnosis 12 years ago).
Patient 23: For this [patient participation in RECs] that they can see
what is being done. Against it [patient participation in RECs] that
there will be maybe a pushing [due to own profit] in order to get it
[drug] developed.
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Discussion
To our knowledge, this is the first empirical study to specifically
explore stable patients’ perceptions of being REC members. The most
commonly mentioned advantageous aspects were: (i) potential benefit
for affected patients and (ii) the disease burden of the patients, which
enables them to add new perspectives on certain aspects of the disease.
Surprisingly, although the interviewees were informed that par-
ticipation in CTs does not lead to any personal benefit in terms of
changes in therapy, they still anticipated personal benefit as one of
the main incentives for the involvement of patients in RECs. This
might be seen as a biasing factor affecting proponents of this idea,
because the hope of long-term benefit for oneself might make one
overlook the risks of participating. Considering this as an indicator
for a persistent therapeutic misconception disqualifies this as an
argument for involving patients in RECs.
However, this biasing factor does not seem to operate on a
broader scale. This presumption is supported by the data of a large
cross-sectional survey exploring community understanding of med-
ical RECs [19]. According to this study the majority of the respon-
dents were aware of the role of RECs.
The second most-mentioned motivation was disease-related
knowledge, particularly regarding the accompanying psychological
and physical strains, which could allow RECs to obtain additional
insight into a specific medical condition. Generally, patients believed
themselves to be most familiar with their specific medical issue and
this specific aspect has not yet been addressed by RECs.
Interestingly, our cohort, with a relatively high average age of
almost 65 years, had similar views to participants in a study investi-
gating young participants’ views on composition of RECs (mean: 16
years). Overall, participants expressed the need for a broader view
provided by lay people [20].
Amongst the negative aspects mentioned in our cohort were
patients’ lack of knowledge compared to experts, and potential diffi-
culties in assessing the consequences of decisions made in the con-
text of complex studies. Similarly, professional expertise was
considered important among young people [20].
Nevertheless, the argument that lack of medical knowledge could
count against patients’ inclusion in decision-making is not tenable.
As stated by Edwards et al. [10], it is not the task of RECs to judge
the competence of patients. As in the shared decision-making model,
participating patients would have to be properly provided with all
relevant information (e.g. risks and potential benefits) before
engaging in REC decisions.
Overall, stable patients seem to be particularly appropriate decision-
makers as they suffer from a chronic disease with a significant burden
[21–24]. Due to the relatively slow progression and associated
mortality of, e.g. diabetes compared to acute diseases, stable patients
are more likely to benefit from future research [23, 25]. Therefore,
REC decisions on CTs might affect them indirectly over the medium-
term, and the problem of ‘therapeutic misconception’ could have a
less prominent role [6]. The most important ethical consideration
favouring the inclusion of stable patients is the need to respect patient
autonomy. In order to meet this requirement, affected patients should
have the opportunity to participate in decision-making in RECs
through their representatives. It has been claimed before that quali-
fied individuals are in the best position to decide which risks are
acceptable for them [10]. From this point of view, the exclusion of
competent patients from RECs can be seen as a form of paternalism,
contradicting the concept of shared decision-making. Shared deci-
sion-making—in a clinical setting—means that neither the physician
(‘paternalism’) nor the patient (‘informed choice’) on his own decide
what is going to be done (e.g. what kind of treatment). Instead, the
decision is made together [26]. This requires the ability of an individ-
ual to make his or her own, independent choices and respecting
patients’ perspectives as being just as valuable as experts’ perspectives
[26, 27]. The impression of RECs as a paternalistic characterized
decision-making body [10, 28] could be countered by enhancing
patients’ autonomy through involving them in decision-making.
Limitations
The limitations of this current study relate to its qualitative design
and relatively low number of participants: the subjectivity of data
analysis and the limited generalizability of the results that we
obtained from German-speaking patients, Furthermore, 10 out of 36
persons could not say anything about the idea of patients as members
of RECs because they were lacking respective knowledge. Since our
investigation only focused on stable patients, generalizable statements
about other patient groups are limited. Another possible limitation
could be the overrepresentation of male patients (88.5%). However,
an epidemiological study showed that 80% of gout patients were
male [29]. Also, a review showed a male excess in diabetes mellitus I,
whereas diabetes mellitus II seemed to be fairly distributed among
both sexes [30]. Generally, it cannot be ruled out that supposedly
healthy lay members suffer from a chronic disease themselves, in
which case their decision-making may also be affected.
Conclusion
From the previous considerations we conclude that stable patients
appear to be suitable as REC members in the field of clinical research.
This is particularly true for CTs in which novel treatment technologies
will be evaluated in affected but stable patients. The reasons for this
are various: First, it can be argued that respect for patients’ autonomy
as one of the four fundamental principles of medical ethics requires the
involvement of patients instead of healthy third parties (e.g. physicians,
ethicists and lay members). Furthermore, the interviews revealed a ten-
dency towards the idea of involvement of stable patients. The primary
stated motivation for this was the improvement of therapeutic options
in the future. This seems to be supported by the fact that chronic dis-
eases such as diabetes commonly have a slowly progressive clinical
course over several years and do not pose an acute threat to life com-
pared to, e.g. advanced stages of cancer. In addition to this idea of
being able to influence new therapeutic options in the future, there are
presumably further reasons why it could be appealing for stable
patients to be part of RECs. Taking part in decision-making regarding
CTs could create a feeling of inclusion and respect for patient
Table 5 Negative aspects of being members of RECs
Patient 13: He/She [patient] does not have the overview of the whole
thing [study], of what was and what might come (…). The patient
cannot determine this (diabetes diagnosis 40 years ago).
Patient 24: They [patients] cannot decide, because they [patients] have no
knowledge. They [patients] only can say if this [treatment, drug] would
be something for me, but if it [treatment, drug] is really good, that is
something they cannot decide (…) (diabetes diagnosis 41 years ago).
Patient 28: Because I think that we as ordinary mortals do not really
have an idea what really goes on [diabetes diagnosis 12 years ago].
Pat 29: (…) I need to leave this [decision] to the experts (gout diagnosis
1 year ago).
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perspectives. In this way, early integration of persons affected could
influence the general acceptance of research in a positive manner. In
contrast to terminally ill patients, stable patients are more likely to be
able to fulfil the demanding work of a REC member because of their
better health condition. Relatively slow disease progression with pos-
sible stable phases under therapy, comparatively good life expectancy
and diverse treatment options especially in early stages may prevent
stable patients from experimental treatment approaches.
The improvement in quality of life in the long-term instead of a
short-term prolongation of life expectancy appears to be the primary
objective for many of the stable patients. Therefore, the possible
objection that stable patients could generally have a bias towards
approving research on novel treatment technologies is not applic-
able. Patients could play an important role when it comes to the
benefit-risk assessment of future therapeutic interventions. The main
additional benefit of this patient group, compared to healthy REC
members, is the disease-burden that these patients are aware of and
the direct insight into patients’ perspectives that they could provide.
For practical purposes it could generally make sense to reach out to
stable patients that match the inclusion criteria of the planned study.
The patients included in RECs should not take part in the study them-
selves in order to avoid biased opinions. Another important point is
that patients would have to be properly informed about their role in the
REC as affected patient representatives. By excluding patients from tak-
ing part in the trial and by providing detailed information the influence
of therapeutic misconception should be reduced. A point of concern in
this context could be that patients who take part in decision-making
but do not participate in the study themselves, may overlook potential
risks to participants of the trial by attaching greater weight to potential
long-term benefits. To counter this, patients could have an advisory
instead of a decision-making role on RECs.
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